S-1 Withdrawal Removes Potential Dilution
According to a filing submitted to the U.S. Securities and Exchange Commission on Monday, Advanced Biomed requested the withdrawal of its Registration Statement on Form S-1 under Rule 477.
The company said it had decided not to proceed with the registered offering “at this time” and confirmed that no securities were sold or will be sold under the registration statement.
The withdrawal removes the prospect of an immediate equity offering, a development that investors often view favorably because it avoids potential shareholder dilution.
Filing Details
The withdrawn registration statement was originally filed on July 23, 2025. Advanced Biomed requested that the SEC consent to the withdrawal of the filing and all related amendments, stating that the offering would not move forward.
The company did not disclose whether it plans to pursue an alternative capital-raising strategy in the future.
Trading Metrics
Advanced Biomed has a market capitalization of approximately $14.7 million. The stock has traded between a 52-week low of $3.61 and a 52-week high of $15.20.
According to Benzinga Edge Stock Rankings, ADVB has a positive price trend across the short-, medium- and long-term time frames.
Photo Courtesy: Joyseulay on Shutterstock.com
